A biopharmaceutical company that pioneers antisense and RNA-targeting drug technology to develop treatments for cardiovascular, neurological and rare diseases.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Ancora | 40 | Trimmed -7% | 2,215 | $175,627 | 0.0% |
| Paul Tudor Jones / Tudor | 63 | Trimmed -43% | 39,400 | $3,124,026 | 0.0% |
| Steve Cohen / Point72 | 76 | Trimmed -8% | 34,200 | $2,711,718 | 0.0% |
| Filed | Insider | Role | Shares | Value | |
|---|---|---|---|---|---|
| 2026-07-31 | Hayden Michael R | director | 20,000 | $1,058,700 | Form 4 |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-09-24.